The neuroprotective agent must have a predominant effect on the identified pathogenic mechanism. De-prenyl was thought to afford cellular neuroprotection by decreasing the propensity of MAO B to produce free radical compounds resulting from deamination of catecholamines [6] . However, as has been subsequently pointed out by others, including the PDSG [1], the termination of dopamine synaptic action is primarily mediated by reuptake and MAO type A is actually the isoform which predominates in striatal neurons (rather than type B). Consequently, inhibitors of MAO A have been postulated as potentially superior neuroprotective agents. Another confounding factor in the literature is the recent report that deprenyl may also rescue neurons through a neuro-trophic-like effect [11] . Neuroprotection must be operationally defined in a way that allows experimental study and, more specifically, measurement. The DAT ATOP study relied on clinical assessment for quantifying neuroprotection. Unfortunately, there is a major gap in our knowledge concerning the pathological evolution of IP and its clinical progression. Clinical features seem to appear only when some half of the normal complement of nigro-striatal dopaminergic neurons remain; from that point onward the relationship becomes uncharted. However, even if this relationship were known, it would be an impossible task to distinguish symptomatic from neuroprotective effects if clinical indices were the sole measuring instrument. The theoretical possibility of differentiating the two mechanisms by wash-in and wash-out examinations [4] is saddled with the problem of separating a delayed (post wash-in) or prolonged (post wash-out) symptomatic effect from neuroprotection. A good example of this complication was provided by the DATATOP study which demonstrated, by an extended wash-out [1] , that part of the symptomatic effect had initially been missed [2] . Using clinical assessment as the sole yardstick, the DATATOP study showed that the symptomatic effect of deprenyl may have been sufficient to explain the difference in outcome for the patients treated with deprenyl versus placebo [12] . It also showed that this effect was sustained after a wash-out period, and remained even if the subjects whose clinical measures obviously improved initially (after 1 month of treatment) were excluded from the analysis. Neuroprotection could be neither proved nor disproved [1] . Even a divergent evolution (i.e., a slower progression after wash-in of the treated subjects versus controls [12] , which would require serial clinical evaluations to be noticed) may be misleading. The clinical evolution of a partially symptomatically treated patient may also differ from the natural clinical evolution in an untreated patient. To avoid such a problem in the future, it has been suggested that only drugs without short-term symptomatic effect be tested. This approach faces a difficulty and a paradox. The difficulty is to assess the absence of any symptomatic effect. In this respect, the very carefully designed DATATOP study is again exemplary, as it disclosed the significant symptomatic effect of deprenyl that some previous studies had failed to identify. The paradox is that such an approach discards any drugs which potentially are neuroprotective and symptomatically beneficial. Certain both symptomatic treatments of IP may have neuroprotective effects e.g.: (1) dopaminergic agonists -which may reduce free-radical production by decreasing dopamine turnover because of their direct action on dopaminergic pre-synaptic auto-receptors [13]; (2) amantadine -which reduces dopamine reuptake [14] (and likewise may reduce uptake of toxins like MPTP). Amantadine is also an NMDA antagonist (possibly protecting against excitotox-icity) [14] . One can speculate that amantadine could have been substituted for deprenyl in the DATATOP study and would have led to the same conclusions. Symptomatic treatments may also improve prognosis by means other than neuroprotection. For example, reduced cardiovascular catastrophies have been reported in patients taking bromocriptine with levodopa compared with levodopa alone [15] . It seems unfortunate to exclude evaluation of these treatments as protective agents in an attempt to simplify the interpretative process. We consider that the importance of generating an operational definition has been overlooked in human studies designed to evaluate neuroprotection. If this issue is not resolved, the DATATOP destination will be revisited. Consequently we suggest that the term neuroprotection be avoided when referring to purely clinical studies in the absence of a practical operational definition. What possibilities are there for assessing neuroprotection? The relationship between nigral cell counts and the striatal fluorodopa uptake, as measured by PET, has recently been shown to be linear [16] . With accumulating evidence that the rate of neuronal death in IP exceeds that of normal aging [17, 18] , we suggest measuring the neuroprotective effect in terms of reducing the velocity of abnormal nigral decay in IP. Neuroprotection of 100% would decrease the speed of neuronal death to that of normal aging. The current reproducibility of fluorodopa PET [19] , coupled with the relatively slow natural evolution of IP, suggests that a large number of subjects would have to be studied for a long'period of time. We estimate 2 Vingerhoets/Uitti/Calne Deprenyl and the Issue of Neuroprotection that at least 30 patients (and as many controls) would have to be scanned twice over an interval of 7 years, to identify (with a power of 80%) a completely neuroprotective treatment (i.e. one that slowed the rate of nigral neuronal loss to that of normal aging). We realize that substantial investments of time and resources are required to complete clinical studies of this kind. However, as in the case of striatal transplantation [20] , such an investment may be warranted and allow expansion of potential neuroprotective agents to include more than merely the 'losers on the symptomatic battlefield'.
